How is delivering vitamins to mothers-to-be in Indonesia connected to helping smallholder farmers grow diverse crops in northern Africa? How are providing family planning options in the Middle East linked to closing nutrition gaps in the United States? And how does it all connect back to slowing poverty through healthcare?

These stories are more interconnected than you think. Because whether we’re talking about agriculture or healthcare, the largest obstacles around the globe–the ones that most affect our lives–often come down to access: who has it, who needs it, and how can we better deliver it through our vision of Health for All, Hunger for None.

Captivating Stories of Access

We invited employees and partners to turn on their cameras and give us a glimpse into their world and their work, showing us just how they are changing lives for the better through the important work of securing a better life FOR ALL through healthcare and agriculture. Worldwide, they share a common goal: a greater need for access to health and nutrition.

“It’s one of the most gratifying things I can do…to give something back.” Mark Edge is Director of Partnerships, Seeds and Traits Business Development. As a self-proclaimed “small town farm kid from Iowa,” he never thought he’d one day spend a large portion of his career in Africa, helping Smallholder Farmers and underserved communities improve on their crop yields and productivity.

View original content here

Bayer

Bayer

Bayer: Science For A Better Life

Bayer is a global enterprise with core competencies in the Life Science fields of health care and agriculture. Its products and services are designed to benefit people and improve their quality of life. At the same time, the Group aims to create value through innovation, growth and high earning power. Bayer is committed to the principles of sustainable development and to its social and ethical responsibilities as a corporate citizen. In fiscal 2015, the Group employed around 117,000 people and had sales of EUR 46.3 billion. Capital expenditures amounted to EUR 2.6 billion, R&D expenses to EUR 4.3billion. These figures include those for the high-tech polymers business, which was floated on the stock market as an independent company named Covestro on October 6, 2015. For more information, go to www.bayer.com.

More from Bayer